Single-Dose Ebola Vaccine Effective in Nonhuman Primates

This article originally appeared here.
Share this content:
Single-Dose Ebola Vaccine Effective in Nonhuman Primates
Single-Dose Ebola Vaccine Effective in Nonhuman Primates

(HealthDay News) -- A quick-acting, single-dose Ebola vaccine is safe and effective in nonhuman primates, and may lead to a new human vaccine, U.S. researchers reported Wednesday. The study was published online April 8 in Nature.

The experimental vaccine is effective against the West African Makona strain of Ebola Zaire virus. The vaccine uses a harmless virus that has a part of the Ebola virus inserted into it. In nonhuman primates, the vaccine triggered an immune response against Ebola.

"These findings may pave the way for the identification and manufacture of safer, single-dose, high-efficiency vaccines to combat current and future Ebola outbreaks," Thomas Geisbert, Ph.D., a professor of microbiology and immunology at the University of Texas Medical Branch at Galveston, said in a university news release. "We are excited at the possibility of helping develop a way to stop this deadly disease. We have a lot more work to accomplish but it's important to note that this is a big step," he added.

With a growing population in West Africa, there will be increased contact between people and Ebola virus hosts such as bats, potentially leading to other large outbreaks, the researchers said. While efforts to develop new vaccines may not be helpful in the current Ebola outbreak, they could prove important in fighting future outbreaks.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Vit D Independently, Inversely Tied to Cholesterol in Children

Vit D Independently, Inversely Tied to Cholesterol in ...

Gene variants do not modify the associations of 25(OH)D with lipids

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Ibalizumab Active in Multidrug Resistant HIV-1 Infection

Lower degree of susceptibility to ibalizumab for nine of 10 patients with virology failure, rebound

Weight Gain After Quitting Smoking May Up T2DM Risk

Weight Gain After Quitting Smoking May Up T2DM ...

But temporary increase in type 2 diabetes risk does not attenuate benefits on total, CVD mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »